CClinicalTrials.gg
Not yet recruitingNCT07566403OROBICAUpdated May 6, 2026

Overviewing Real-World Outcomes to Boost Interventional Management of CAlcified Coronary Lesions: the OROBICA Registry.

An observational study in Coronary Artery Disease (CAD), Calcific Coronary Arteriosclerosis and Intravascular Lithotripsy; Rotational Atherectomy; OFDI, sponsored by Papa Giovanni XXIII Hospital. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Papa Giovanni XXIII Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Study summary

The OROBICA (Overviewing Real-World Outcomes to Boost Interventional Management of CAlcified Coronary Lesions) Registry is a multicenter, ambispective, real-world observational study designed to evaluate clinical, procedural, imaging, and economic outcomes of patients undergoing percutaneous coronary intervention (PCI) for severely calcified coronary artery disease.

Coronary artery calcification represents one of the main determinants of procedural complexity and adverse outcomes in contemporary interventional cardiology. Despite the increasing availability of advanced calcium-modification technologies and intracoronary imaging techniques, evidence regarding the optimal treatment strategy in real-world clinical practice remains limited, particularly among high-risk and complex patients often underrepresented in randomized trials.

The OROBICA Registry aims to systematically collect longitudinal data from all-comer patients treated for severely calcified coronary lesions using contemporary PCI strategies, including intracoronary imaging guidance (IVUS/OCT), rotational atherectomy, orbital atherectomy, intravascular lithotripsy, specialty balloons, and combined calcium-modification approaches.

The primary objective is to assess clinical and procedural outcomes, with particular focus on target vessel failure (TVF). Secondary and exploratory objectives include evaluation of procedural success, imaging findings, predictors of adverse outcomes, healthcare resource utilization, and economic impact associated with the treatment of calcified coronary lesions.

The registry is designed as a flexible research platform intended to support future hypothesis-generating analyses and provide real-world evidence to improve personalized management strategies for calcified coronary artery disease.

02

Conditions studied

  • Coronary Artery Disease (CAD)
  • Calcific Coronary Arteriosclerosis
  • Intravascular Lithotripsy; Rotational Atherectomy; OFDI
  • Orbital Atherectomy
  • Optical Coherence Tomography (OCT)
  • Intravascular Ultrasound
  • Percutaneous Coronary Intervention

Keywords

  • Coronary calcifications
  • coronary artery disease
  • percutaneous coronary intervention
  • intravascular imaging
  • atherectomy
  • intravascular lithotripsy
  • rotational atherectomy
  • orbital atherectomy
  • cutting balloon
  • target vessel failure
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The OROBICA Registry will include adult patients undergoing percutaneous coronary intervention (PCI) for severely calcified coronary artery disease in routine clinical practice. The study population consists of all-comer patients treated for complex calcified coronary lesions, including individuals with stable coronary artery disease, acute coronary syndromes, multivessel disease, left main disease, bifurcation lesions, chronic total occlusions, and high-risk clinical or anatomical features.

Inclusion criteria

  • Patients undergoing percutaneous coronary intervention (PCI) for severely calcified coronary lesions, angiographically defined as radiopacities noted without cardiac motion before contrast injection, generally involving both sides of the arterial wall.
  • Patients undergoing PCI for calcified coronary lesions with intracoronary optical coherence tomography (OCT) showing at least one of the following features:

    • calcium arc ≥180°
    • calcium thickness ≥0.3 mm
    • calcium length ≥3 mm
    • presence of calcified nodules
  • Patients undergoing PCI for calcified coronary lesions with intravascular ultrasound (IVUS) showing at least one of the following features:

    • calcium arc ≥180°
    • concentric or superficial calcium with extensive acoustic shadowing
    • presence of calcified nodules

Exclusion criteria

Exclusion Criteria:

  • Lack of availability of essential clinical or procedural data.
  • Refusal or withdrawal of informed consent for the prospective component of the registry, when applicable.
  • Exercise of the right to object to data processing, according to applicable data protection regulations.
04

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
3,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Imaging group

    Patients undergoing intravascular imaging-guided PCI

    Procedure: Percutaneous coronary intervention with or without stent implantation

  • Debulking group

    Patients undergoing PCI with advanced calcium-modification devices

    Procedure: Percutaneous coronary intervention with or without stent implantation

Interventions

  • ProcedurePercutaneous coronary intervention with or without stent implantation

    In this registry patients will undergo PCI of severely calcified coronary arteries

05

What researchers measure

Primary outcomes

  1. Rate of Target Vessel Failure (TVF)

    Defined as composite of Cardiac Death, Target vessel Myocardial Infarction and Clinically-Driven Target Vessel Revascularization

    Time frame: 1, 2 and 5 years

Secondary outcomes

  1. Rate of Major Adverse Cardiovascular Events (MACE)

    Defined as composite of all-cause death, myocardial infarction (MI), stroke, clinically-driven target vessel revascularisation (CD-TVR) and hospitalization for cardiovascular causes

    Time frame: 1, 2 and 5 years

Other outcomes

  1. Rate of MACE and Repeat Revascularization across Calcium Modification Techniques.

    Evaluation of the incidence of Major Adverse Cardiovascular Events (MACE) and Target Lesion Revascularization (TLR) in relation to the specific calcium modification strategy used: rotational atherectomy, orbital atherectomy, intravascular lithotripsy (IVL), excimer laser, or combined strategies.

    Time frame: 30 days, 1, 2 and 5 years

  2. Total Procedural Costs and Healthcare Resource Utilization.

    Assessment of total economic burden including costs of specific interventional materials/devices, total procedure duration, length of index hospital stay, and rate of all-cause hospital readmissions.

    Time frame: From index procedure up to 12 months.

  3. Predictors of Severe Coronary Calcification and Procedural Complexity.

    Identification of clinical, angiographic, intravascular imaging, and biochemical markers (e.g., renal function, calcium-phosphorus metabolism) associated with the presence of severe calcification and the requirement for advanced calcium modification tools.

    Time frame: Baseline (at the time of index procedure).

06

Study locations

1 site
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07566403
Lead sponsor
Papa Giovanni XXIII Hospital
Responsible party
Francesco Moretti (Principal Investigator, Papa Giovanni XXIII Hospital) — Principal investigator
First posted
May 5, 2026
Start date
Jun 30, 2026 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2036 (estimated)
Last update
May 6, 2026

Study contacts

Francesco Moretti, MD
principal investigator · Papa Giovanni XXIII Hospital, Bergamo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion